The World Health Organization (WHO) took a leading role in global pharmacovigilance efforts. In 1968, WHO established its International Drug Monitoring Programme, which initially involved ten countries (Australia, Canada, Denmark, Ireland, Netherlands, New Zealand, Sweden, United Kingdom, United States, West Germany (now part of Germany)). This program aimed to improve drug safety by encouraging countries to report ADRs systematically.

In 1978, WHO set up the Uppsala Monitoring Centre (UMC) in Sweden to collect, analyze, and distribute data on adverse drug reactions from around the world. The UMC became the operational arm of the WHO Programme for International Drug Monitoring (PIDM), creating the world’s largest database of individual case safety reports (ICSRs).

Evolution in Europe and the United States

In the United States, the Food and Drug Administration (FDA) established its Adverse Event Reporting System (AERS) and its current counterpart, the FDA Adverse Event Reporting System (FAERS), to monitor drug safety post-marketing.

In Europe, the European Medicines Agency (EMA) established the EudraVigilance database in 2001, which collects reports of suspected ADRs for medicines authorized in Europe. The EMA Pharmacovigilance Risk Assessment Committee (PRAC) was created to assess safety issues in medicines.

ICH Guidelines and Global Harmonization

The development of pharmacovigilance was further advanced with the formation of the International Council for Harmonisation (ICH) in 1990. ICH’s E2E Guidelines on Pharmacovigilance provide international standards on risk management, signal detection, and adverse event reporting. This initiative aimed to harmonize regulations between the U.S., Europe, and Japan, making the exchange of drug safety information more consistent globally.

Pharmacovigilance in the 21st Century

With advancements in technology, pharmacovigilance has evolved into a more robust, data-driven science. Key developments include:

1. Big Data and Artificial Intelligence (AI): The use of AI and machine learning for data mining in pharmacovigilance has revolutionized signal detection and ADR reporting.

2. Electronic Health Records (EHRs): These allow real-time monitoring of patient data and contribute to more efficient detection of drug-related issues.

3. Real-World Evidence (RWE): PV now also includes analyzing real-world data to assess the safety and effectiveness of drugs in broader patient populations.

4. Patient-Centric Reporting: The role of patients in reporting ADRs has been emphasized, allowing for a more comprehensive understanding of drug safety in everyday clinical use.

The Role of Pharmacovigilance in Regulatory Frameworks

Regulatory authorities have established strict guidelines for the submission of pharmacovigilance data. The requirement to submit Periodic Safety Update Reports (PSURs) and the implementation of Risk Management Plans (RMPs) are crucial for maintaining drug safety. Regulatory bodies have expanded the scope of pharmacovigilance from ADR monitoring to include medication errors, product quality issues, and drug misuse or abuse.

Current Global Challenges in Pharmacovigilance

While pharmacovigilance systems have improved globally, challenges remain:

• Underreporting: Adverse drug reactions are still underreported in many countries, particularly in low- and middle-income regions (India, Nigeria, Sierra Leone, Pakistan, Bangladesh, South Africa, Kenya, Egypt, Philippines, Vietnam).
• Global Disparities: Differences in healthcare infrastructure and regulatory frameworks affect the effectiveness of pharmacovigilance systems across the world.
• Integration of New Technologies: The use of AI and big data analytics is growing, but integrating these technologies into traditional pharmacovigilance systems remains a challenge.
• COVID-19 Pandemic: The rapid development and deployment of COVID-19 vaccines and treatments highlighted the need for accelerated pharmacovigilance processes while maintaining safety standards.

Conclusion

Pharmacovigilance has grown from a reactive approach to adverse drug events into a proactive and integrated system, focusing on risk management and safety signal detection. While significant progress has been made, particularly with the integration of new technologies and harmonized global efforts, the field continues to evolve. Its importance in ensuring the safety of medicines and protecting public health remains indisputable, making it an essential component of modern healthcare systems.